Stephen Ayers

MBA | Seeking Alpha analyst | Biotech deep dives ↓

[Stephen Ayers @meremrtl]

The coolest title I've written, and a pretty interesting story, too. $CMPS https://t.co/PG09S9uzTK

[Tut C🅰️pital @kingtutcap]

Screenshot of my portfolio today

[Not Jerome Powell @alifarhat79]

BREAKING: ETH just dropped its new logo

[Stephen Ayers @meremrtl]

@PCHate_ What was his sprint speed?

[Stephen Ayers @meremrtl]

$PRAX https://t.co/RAUkcLirXE

[Stephen Ayers @meremrtl]

$PRAX ulixacaltamide in Essential Tremor.

[Stephen Ayers @meremrtl]

Nice.

[Adam Schefter @AdamSchefter]

Statement from Chairman George H. McCaskey and President & CEO Kevin Warren:

[Stephen Ayers @meremrtl]

A common misconception in biotech is that prescribers (doctors, PAs, and nurse practitioners) control market uptake of new drugs. They actually have far less power than most investors assume. Anyone can write a script. But if payers won’t cover it (or impose prior authorization, step therapy, or prohibitive copays), patients almost never get the drug.

The true bottlenecks in the biotech market are payers and Pharmacy Benefit Managers (PBMs), not prescribers.

[Stephen Ayers @meremrtl]

@seedy19tron @E_McClintock_ That's a straw man.

Signing off. Thanks for the discussion and sorry I upset you with my actual argument ("don’t over-claim superiority without direct comparative data").

[Stephen Ayers @meremrtl]

@seedy19tron @E_McClintock_ Oh, boy. I see where this is going.

I'm "blatantly misrepresenting things" by saying that obe cannot claim superiority over existing treatments, especially without H2H data.

I'll disengage since you are getting quite upset.

[Stephen Ayers @meremrtl]

@E_McClintock_ @seedy19tron Cannot really claim superiority without H2H data. And, cross-trial comparison limitations aside, induction data is on par with existing treatments.

[Stephen Ayers @meremrtl]

@mrhighway_y Thank you for sharing your thoughts!

[Stephen Ayers @meremrtl]

@JackMan724444 @BioRichesRags @peopleofmelos @seedy19tron Again, that's not true. Are you able to see my replies? I'm very confused.

[Stephen Ayers @meremrtl]

@JackMan724444 @mikehunt492226 @seedy19tron @adamfeuerstein LOL. Wow, the insults are hitting hard now, Jack Man.

[Stephen Ayers @meremrtl]

@TheBenStadler @seedy19tron I did, on SA.

This is X. It is social media/shorthand format.

Oh, it's "silly." Ok. Thanks for that.

Alright, well, I gotta get back to work on my silly model on another name, so I am signing off on this great discussion we had, Ben. Take care!

[Stephen Ayers @meremrtl]

@JackMan724444 @BioRichesRags @peopleofmelos @seedy19tron lol.. a "hater." I've literally been BUY (immediately following P3 UC induction data at $68/share) --> HOLD (after it became apparent that the company was going it alone) on the name, and I am called a "hater."

[Stephen Ayers @meremrtl]

@seedy19tron But, actually, yes, I am appreciative that you took the time to think of base/bear cases. Thank you!

[Stephen Ayers @meremrtl]

@TheBenStadler @seedy19tron Yes, AROUND $92.

But was $91.59/share in March. I then bumped up POS following maintenance data and the value is now $95.81.

Both of those values are around $92 (shorthand for X).

Again, details are on SA.

What exactly are you arguing?

[Stephen Ayers @meremrtl]

@E_McClintock_ @seedy19tron More feasible pricing assumptions.

You have to assume heavy rebates in order to win formulary placement against entrenched, now-biosimilar-eroded TNFs and against incumbent orals

[Stephen Ayers @meremrtl]

@BioRichesRags @peopleofmelos @seedy19tron It means that I apparently can't become familiar with other lines of work/knowledge.

Actually, it's a very low IQ way of dismissing anything I say.